OUH STUDIES

Studies currently being run within Oxford University Hospitals NHS Foundation Trust.

Showing 371 - 380 of 797 studies

Cancer and neoplasms

Window-of-opportunity clinical trials platform for evaluation of novel treatment strategies in renal cell cancer.

Any patient suspected of having surgically resectable clear cell renal cell carcinoma (ccRCC) (M0/M1) is suitable for screening for WIRE. The study will provide participants with exposure to novel agents as monotherapy and in combination during the period of time between the decision to undergo surgery and resection. This period of time is 4 weeks due to UK cancer targets, during which patients would otherwise remain untreated. The aim of WIRE is to determine if the novel agents will deliver ...

GO TO STUDY Go

WATCHMAN FLX versus NOAC for EMbolic ProtectION in the Management of Patients with Non-Valvular Atrial Fibrillation

The Champion AF study is designed to determine if left atrial appendage closure with the WATCHMAN FLX Device is a reasonable alternative to Direct Oral Anticoagulant (NOACs) in patients with non-valvular atrial fibrillation. Patients in this study will be randomized to either receive the WATCHMAN FLX Device or a course of NOACs patients will be assessed over a period of up to 5 years.

GO TO STUDY Go

Cancer and neoplasms

ALLTogether1– A Treatment study protocol of the ALLTogether Consortium for children and young adults (1-45 years of age) with newly diagnosed acute lymphoblastic leukaemia (ALL)

Acute Lymphoblastic Leukaemia (ALL) is the commonest cancer of children and young adults with over 400 cases diagnosed each year in the UK. While over 90% of children with ALL are cured, some people’s disease is harder to treat than others. ALLTogether1 investigates whether treatment can be reduced for children with the highest chance of cure, and whether the addition of new drugs improves the chance of cure for those whose disease is most likely to relapse. In the UK, ...

GO TO STUDY Go

Blood

MOdern Treatment of Inhibitor-PositiVe PATiEnts with Haemophilia A – An International Low-Interventional Pragmatic Investigator Initiated Trial

Inhibitor development is the most serious treatment-related complication of replacement coagulation factor VIII (FVIII) therapy for patients with haemophilia A. Immune tolerance induction (ITI), which involves intensive treatment with plasma-derived (pdFVIII) or recombinant FVIII (rFVIII), is the only clinically proven strategy for eradication of inhibitors. The bispecific antibody emicizumab is approved for use in patients with and without inhibitors to prevent bleeding but does not eliminate inhibitors. MOTIVATE aims to capture different approaches to the treatment and management of patients ...

GO TO STUDY Go

Cancer and neoplasms

A pilot study in high intensity focused ultrasound ablation of resectable soft tissue sarcoma and small symptomatic desmoid tumours

Around 3,300 people are diagnosed with soft tissue sarcoma (STS) each year in the UK, and a significant proportion of STS diagnoses are in people aged under 30 years. STS can arise from various tissue types and is comprised of over 50 tumour types. Although STS is treated with a combination of surgery, radiotherapy and chemotherapy, the prognosis is relatively poor with a five-year survival rate of 54%. There is a an unmet need for further treatment modalities in STS. ...

GO TO STUDY Go

Neurological

The Parkinson’s Precision Medicine Initiative (PPMI) Clinical - Establishing a Deeply Phenotyped PD Cohort

PPMI2.0 is a broad program, expanding the goals of the original PPMI study that was started in 2010 and has recruited 424 patients with Parkinson's disease (PD), 196 healthy controls, 600 patients with genetic mutations linked to PD, and 65 prodromal participants. The PPMI study has made substantial progresses in PD research with more than 170 publications and 2 million downloads of PPMI data for research purposes worldwide. However, there is a consensus that a new PPMI cohort is ...

GO TO STUDY Go

Cancer and neoplasms

PREMIUM: PeRioperative Encorafinib+binimetinib in BRAFV600 MUtant clinically detected AJCC stage III(B/C/D) or oligometastatic stage IV Melanoma (PREMIUM)

The PREMIUM trial is multi-centre, open label, two-arm, randomised phase II feasibility trial looking at the role of pre-operative encorafinib plus binimetinib (EncoBini) compared with the standard post-operative therapy, in patients with potentially resectable melanoma. Eligible patients will be randomised to receive either 8 weeks of pre-operative EncoBini, followed by surgery, then up to 44 weeks of EncoBini (EncoBini Arm); or to receive up to 52 weeks of the standard post-surgery treatment offered at their participating site (Standard Arm). ...

GO TO STUDY Go

Stroke

The Thames Valley Young Stroke Study (TV-YSS): a prospective cohort study

Up to 10% of strokes occur in patients aged under 55 years (“young stroke”) causing a large numbers of years lost to ill-health and premature death. More worryingly, the number of new cases of young stroke (“incidence”) appears to be increasing in recent decades in high-income countries.Reasons for this apparent increase are unclear. One explanation is that the observed increase in new cases coincided with the changes in the burden of treatable vascular risk factors among young adults, such as high ...

GO TO STUDY Go

Injuries and accidents

World Hip Trauma Evaluation (WHiTE) Platform – a framework for clinical trials for fragility hip fracture in those aged 60 and over

Hip fracture is one of the biggest challenges facing patients and healthcare systems. Worldwide there are 1.3 million hip fractures with more than 70,000 hip fractures in the UK every year. These figures are projected to rise to more than 6 million by 2050 worldwide.People suffering hip fracture have a 30-day mortality of 7%, a 1-year mortality of 25% and experience a permanent reduction in their health-related quality-of-life similar to that of a patient with Parkinson’s disease or multiple sclerosis. ...

GO TO STUDY Go

Infection Mental health

Assessing the effects of Coronavirus Disease (COVID-19) on multiple organ systems and impact on quality of life, functional capacity and mental health

Coronavirus disease or COVID-19 is a respiratory viral illness which has affected more than a million people globally. Although the illness mostly affects the lungs, some people can develop damage to other organs. The symptoms of this disease can continue for months after the infection. The purpose of this study is to understand the effects of COVID-19 on the health of the lungs, heart, brain, liver and kidney and assess its effects on the quality of life, mental health and ...

GO TO STUDY Go